By Application
Hot products 
-
Mouse Anti-AQP2 Recombinant Antibody (G-3) (CBMAB-A3359-YC)
-
Mouse Anti-Acetyl SMC3 (K105/K106) Recombinant Antibody (V2-634053) (CBMAB-AP052LY)
-
Mouse Anti-ALPL Antibody (B4-78) (CBMAB-1009CQ)
-
Rabbit Anti-ABL1 (Phosphorylated Y245) Recombinant Antibody (V2-505716) (PTM-CBMAB-0465LY)
-
Mouse Anti-BCL2L1 Recombinant Antibody (H5) (CBMAB-1025CQ)
-
Mouse Anti-C5B-9 Recombinant Antibody (CBFYA-0216) (CBMAB-X0304-FY)
-
Rat Anti-EMCN Recombinant Antibody (28) (CBMAB-E0280-FY)
-
Mouse Anti-CD33 Recombinant Antibody (P67.6) (CBMAB-C10189-LY)
-
Mouse Anti-BANF1 Recombinant Antibody (3F10-4G12) (CBMAB-A0707-LY)
-
Mouse Anti-CD247 Recombinant Antibody (6B10.2) (CBMAB-C1583-YY)
-
Mouse Anti-CIITA Recombinant Antibody (CBLC160-LY) (CBMAB-C10987-LY)
-
Mouse Anti-AKT1/AKT2/AKT3 (Phosphorylated T308, T309, T305) Recombinant Antibody (V2-443454) (PTM-CBMAB-0030YC)
-
Rat Anti-ADAM10 Recombinant Antibody (V2-179741) (CBMAB-A1103-YC)
-
Mouse Anti-ADIPOR1 Recombinant Antibody (V2-179982) (CBMAB-A1368-YC)
-
Mouse Anti-EGR1 Recombinant Antibody (CBWJZ-100) (CBMAB-Z0289-WJ)
-
Mouse Anti-APOA1 Monoclonal Antibody (CBFYR0637) (CBMAB-R0637-FY)
-
Mouse Anti-AAV8 Recombinant Antibody (V2-634028) (CBMAB-AP022LY)
-
Mouse Anti-AKR1B1 Antibody (V2-2449) (CBMAB-1001CQ)
-
Mouse Anti-CARTPT Recombinant Antibody (113612) (CBMAB-C2450-LY)
-
Mouse Anti-DLL4 Recombinant Antibody (D1090) (CBMAB-D1090-YC)
Prostate Cancer
Fig.1 Prostate cancer
Prostate cancer is regarded as glandular cancer or adenocarcinoma, which starts when normal semen-secreting prostate gland cells mutation happens and changes into cancer cells. The majority of prostate cancers are slow-growing; however, some grow relatively quickly. The cancer cells may spread from the prostate to other sites of the body, particularly the lymph nodes and bones. It may initially cause no symptoms. But in later stages it can lead to difficulty urinating, blood in the urine, pain in the pelvis when urinating. The primary risk factors are age, obesity, and family history. Around 99% of cases occur in people over the age of 50 and the average age at the time of diagnosis is around 70. Mutations in BRCA1 and BRCA2 are important risk factors for ovarian cancer and breast cancer in women, have also been implicated in prostate cancer. The expression of Ki-67 by immunohistochemistry may be a significant predictor of patient outcome for men with prostate cancer.
Loading...
Compare
